You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 141 No. 11, October 1981 TABLE OF CONTENTS
  Archives
  •  Online Features
  CLINICAL OBSERVATIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (43)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Methylenedioxyamphetamine

Clinical Description of Overdose, Death, and Review of Pharmacology

Dennis L. Simpson, MD; Barry H. Rumack, MD

Arch Intern Med. 1981;141(11):1507-1509.


Abstract

Methylenedioxyamphetamine is a commonly used "street drug," with a reputation of providing a "good trip." The drug is structurally similar to both mescaline and amphetamine. The following symptoms were found in a patient: sympathomimetic effects, coma, seizures, hyperreflexia, and hyperthermia. The patient's condition was initially stabilized and then deteriorated with uncontrollable hyperthermia, hematologic abnormalities, and coma that culminated in death. Since the hyperthermia is based on both central and peripheral mechanisms, phentolamine (Regitine) mesylate may be the preferred drug to be used in the treatment of future cases. The concept that this drug is primarily a hallucinogen with mild toxicity is erroneous.

(Arch Intern Med 1981;141:1507-1509)



Author Affiliations

From the University of Colorado Health Sciences Center, School of Medicine (Drs Simpson and Rumack), the B. F. Stolinsky Laboratories (Dr Rumack), the Rocky Mountain Poison Center (Dr Rumack), and the Denver General Hospital (Dr Rumack), Denver.


Footnotes

Accepted for publication Sept 23, 1980.

Reprint requests to University of Colorado Health Sciences Center, 4200 E Ninth Ave, Box C-233, Denver, CO 80262 (Dr Rumack).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney
Campbell and Rosner
CJASN 2008;3:1852-1860.
ABSTRACT | FULL TEXT  

The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, "Ecstasy")
Green et al.
Pharmacol. Rev. 2003;55:463-508.
ABSTRACT | FULL TEXT  

The pharmacology and toxicology of "ecstasy" (MDMA) and related drugs
Kalant
CMAJ 2001;165:917-928.
ABSTRACT | FULL TEXT  

Cardiomyopathy Associated With the Smoking of Crystal Methamphetamine
Hong et al.
JAMA 1991;265:1152-1154.
ABSTRACT  

'Eve' and 'Ecstasy' A Report of Five Deaths Associated With the Use of MDEA and MDMA
Dowling et al.
JAMA 1987;257:1615-1617.
ABSTRACT  

Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals
Ricaurte et al.
Science 1985;229:986-988.
ABSTRACT  

Rhabdomyolysis After Ingestion of an Appetite Suppressant
Rumpf et al.
JAMA 1983;250:2112-2112.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1981 American Medical Association. All Rights Reserved.